Form 4: Oramed CSO Kidron Converts PSUs to Common Stock

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, converted 19,000 performance stock units into common stock following the achievement of a specified share price.

Summary

• Miriam Kidron, Director and Chief Scientific Officer of Oramed Pharmaceuticals Inc. (ORMP), reported a change in beneficial ownership.
• On January 22, 2026, 19,000 performance stock units (PSUs) granted on December 31, 2025, vested.
• The vesting occurred because Oramed's common stock achieved a specified price per share.
• Upon vesting, Kidron received 19,000 shares of common stock for no consideration.
• Following this transaction, Kidron directly owns 1,448,664 shares of common stock and 0 performance stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. The vesting of performance-based compensation tied to stock price achievement suggests the company met a key performance indicator, which is generally favorable for shareholder value.

Positives

• The vesting of 19,000 performance stock units indicates that Oramed Pharmaceuticals' common stock achieved a specified price per share, suggesting positive stock performance.
• Miriam Kidron, a key executive, increased her direct ownership of common stock, aligning her interests further with shareholders.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, focusing solely on a past insider transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the vesting of performance-based awards, can signal management's confidence in the company's trajectory, especially when tied to specific stock price achievements. In the pharmaceutical industry, such events often follow positive clinical or regulatory milestones, though this filing does not specify the underlying reason for the stock price achievement.

Related Party Transactions

• Miriam Kidron, as a Director and Chief Scientific Officer, is a related party. The transaction involves the vesting of performance stock units as part of her compensation, which is a standard related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Potentially positive, as the vesting of PSUs due to stock price achievement suggests the company met performance targets, which could reflect positively on shareholder value. Increased insider ownership also aligns management interests with shareholders.
• Employees: No direct impact mentioned, but successful achievement of performance targets can boost morale.
• Management: Miriam Kidron directly benefited from the vesting of her performance-based compensation.

Key Dates

Recommendation

While the vesting of performance stock units due to stock price achievement is a positive indicator of the company meeting internal targets, this Form 4 filing alone does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'strong buy' recommendation. It confirms a positive internal milestone but lacks broader context for a significant change in investment thesis. A 'hold' recommendation is appropriate, pending further detailed financial disclosures.

Keywords

Oramed Pharmaceuticals, ORMP, Miriam Kidron, Form 4, Insider Transaction, Performance Stock Units, PSU Vesting, Common Stock, Beneficial Ownership, Chief Scientific Officer, Director